Search research articles
Contact Us
Filters
Showing results (131-140 of 192) with videos related to
Page
of 20
Sort By:
Oncotarget
|
April 19, 2014
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit
Denis L Fontes Jardim, Debora de Melo Gagliato, Gerald S Falchook, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 27, 2025
Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1K
Carolyn K McCourt, Zihan Wei, Kevin Kalinsky, et al.
The Oncologist
|
December 15, 2025
Intergroup Randomized Phase III Study of Adjuvant FOLFIRI, FOLFOX, or 5-FU/Leucovorin for Stage II/III Rectal Cancer: ECOG-ACRIN E3201
Audrey E Kam, Fengmin Zhao, Neal J Meropol, et al.
Journal of the National Cancer Institute
|
August 18, 2016
Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial
Patricia A Thompson, Erin L Ashbeck, Denise J Roe, et al.
Journal of the National Cancer Institute
|
August 18, 2016
Selenium Supplementation for Prevention of Colorectal Adenomas and Risk of Associated Type 2 Diabetes
Patricia A Thompson, Erin L Ashbeck, Denise J Roe, et al.
Cancer Prevention Research (Philadelphia, Pa.)
|
October 13, 2012
Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention
Patricia Thompson, Denise J Roe, Liane Fales, et al.
JCO Precision Oncology
|
February 20, 2026
Larotrectinib in Patients With Tumors With <i>NTRK</i> Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1E
Neal Akhave, Zihe Song, David S Hong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 19, 2025
Concordance between tumor tissue and plasma DNA genotyping in the NCI-MATCH trial (EAY131)
Mohamed A Gouda, Filip Janku, Ying Yuan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2022
Phase II Study of Copanlisib in Patients With Tumors With <i>PIK3CA</i> Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F
Senthil Damodaran, Fengmin Zhao, Dustin A Deming, et al.
JCO Precision Oncology
|
December 12, 2024
Phase II Study of Sunitinib in Tumors With <i>c-KIT</i> Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V
Lilian T Gien, Zihe Song, Andrew Poklepovic, et al.
Page
of 20
Search research articles
Search
Showing results (131-140 of 192) with videos related to
Sort By:
Page
of 20
Oncotarget
|
April 19, 2014
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit
Denis L Fontes Jardim, Debora de Melo Gagliato, Gerald S Falchook, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 27, 2025
Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1K
Carolyn K McCourt, Zihan Wei, Kevin Kalinsky, et al.
The Oncologist
|
December 15, 2025
Intergroup Randomized Phase III Study of Adjuvant FOLFIRI, FOLFOX, or 5-FU/Leucovorin for Stage II/III Rectal Cancer: ECOG-ACRIN E3201
Audrey E Kam, Fengmin Zhao, Neal J Meropol, et al.
Journal of the National Cancer Institute
|
August 18, 2016
Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial
Patricia A Thompson, Erin L Ashbeck, Denise J Roe, et al.
Journal of the National Cancer Institute
|
August 18, 2016
Selenium Supplementation for Prevention of Colorectal Adenomas and Risk of Associated Type 2 Diabetes
Patricia A Thompson, Erin L Ashbeck, Denise J Roe, et al.
Cancer Prevention Research (Philadelphia, Pa.)
|
October 13, 2012
Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention
Patricia Thompson, Denise J Roe, Liane Fales, et al.
JCO Precision Oncology
|
February 20, 2026
Larotrectinib in Patients With Tumors With <i>NTRK</i> Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1E
Neal Akhave, Zihe Song, David S Hong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 19, 2025
Concordance between tumor tissue and plasma DNA genotyping in the NCI-MATCH trial (EAY131)
Mohamed A Gouda, Filip Janku, Ying Yuan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2022
Phase II Study of Copanlisib in Patients With Tumors With <i>PIK3CA</i> Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F
Senthil Damodaran, Fengmin Zhao, Dustin A Deming, et al.
JCO Precision Oncology
|
December 12, 2024
Phase II Study of Sunitinib in Tumors With <i>c-KIT</i> Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V
Lilian T Gien, Zihe Song, Andrew Poklepovic, et al.
Page
of 20